ETFs positioned on Merck & Co., Inc.

Name Weight AuM 1st Jan change Investor Rating
14.34% 335 M€ -2.16% -
5.61% 30 M€ -0.09% -
2.85% 0 M€ -.--% -
2.80% 0 M€ -.--% -
2.63% 0 M€ -72.95% -
2.08% 7 M€ 0.00%
1.96% 0 M€ -3.37%
1.96% 0 M€ -.--% -
1.96% 0 M€ +11.94% -
1.96% 0 M€ +7.32% -
1.95% 3 M€ -.--%
1.91% 145 M€ -0.45%
1.84% 419 M€ -0.32%
1.50% 0 M€ -4.31% -
1.49% 0 M€ +1.31%
1.43% 420 M€ +2.18%
1.40% 0 M€ +11.32%
1.35% 0 M€ +14.69% -
1.17% 0 M€ -.--% -
1.17% 0 M€ -.--% -
1.17% 0 M€ +15.16% -
1.13% 0 M€ +0.06% -
1.08% 12 M€ +1.86%
1.05% 0 M€ -.--%
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).
Employees
71,000
Calendar
More about the company
Trading Rating
Investor Rating
ESG MSCI
A
surperformance-ratings-light-chart MERCK-CO-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
100.09USD
Average target price
125.88USD
Spread / Average Target
+25.77%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. ETFs Merck & Co., Inc.